GLP-1 Drug Enters Phase 2 Trial to Slow Progressive Multiple Sclerosis

GLP-1 receptor agonists have dominated headlines for their weight-loss and diabetes benefits, but a growing body of research suggests these drugs may have powerful effects on the brain. Neuraly has now dosed the first patient in a Phase 2 trial of pegsebrenatide, a long-acting GLP-1 drug engineered specifically for neurodegenerative disease, in people with progressive multiple sclerosis. This marks a meaningful expansion of GLP-1 research into neurological territory with direct longevity relevance.

Progressive MS is notoriously difficult to treat. Unlike relapsing forms of the disease, it involves a slow, steady loss of nerve function even when inflammatory attacks appear subdued. Existing MS therapies largely target the immune system and reduce relapses, but they offer limited protection against the underlying neurodegeneration driving long-term disability. Pegsebrenatide is being tested as a potential brake on that degenerative process.

The rationale is grounded in preclinical evidence. GLP-1 receptors are present in the brain, and pegsebrenatide has demonstrated the ability to reduce neuroinflammation and slow disease progression in animal models of MS, Parkinson's, and Alzheimer's disease. A prior Phase 2 Parkinson's trial with 255 patients suggested the drug slowed worsening motor symptoms, particularly in patients under 60 — a promising if preliminary signal.

For the longevity field, the implications extend beyond MS. Chronic low-grade inflammation, sometimes called inflammaging, is now recognized as a central driver of age-related decline across multiple organ systems. If GLP-1 therapies can reduce neuroinflammation systemically, they may become part of a broader anti-aging toolkit aimed at preserving cognitive and physical function over decades.

However, caution is warranted. This is an early-stage trial, and preclinical results frequently fail to translate to humans. The drug is not framed as a cure, and the full scope of its neuroprotective effects in people remains unproven. Larger, longer trials will be essential before clinical recommendations can be made.